Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA73007
Max Phase: Preclinical
Molecular Formula: C9H11N3S2
Molecular Weight: 225.34
Molecule Type: Small molecule
Associated Items:
ID: ALA73007
Max Phase: Preclinical
Molecular Formula: C9H11N3S2
Molecular Weight: 225.34
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CS/C(S)=N/N=C(\C)c1ccccn1
Standard InChI: InChI=1S/C9H11N3S2/c1-7(11-12-9(13)14-2)8-5-3-4-6-10-8/h3-6H,1-2H3,(H,12,13)/b11-7+
Standard InChI Key: IFRMECQLFGLWCS-YRNVUSSQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 225.34 | Molecular Weight (Monoisotopic): 225.0394 | AlogP: 2.45 | #Rotatable Bonds: 2 |
Polar Surface Area: 37.61 | Molecular Species: ACID | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 6.00 | CX Basic pKa: 2.65 | CX LogP: 2.43 | CX LogD: 1.46 |
Aromatic Rings: 1 | Heavy Atoms: 14 | QED Weighted: 0.36 | Np Likeness Score: -1.07 |
1. Bharti N, Maurya MR, Naqvi F, Azam A.. (2000) Synthesis and antiamoebic activity of new cyclooctadiene ruthenium(II) complexes with 2-acetylpyridine and benzimidazole derivatives., 10 (20): [PMID:11055329] [10.1016/s0960-894x(00)00446-7] |
2. Greenbaum DC, Mackey Z, Hansell E, Doyle P, Gut J, Caffrey CR, Lehrman J, Rosenthal PJ, McKerrow JH, Chibale K.. (2004) Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi., 47 (12): [PMID:15163200] [10.1021/jm030549j] |
3. Ettari R, Tamborini L, Angelo IC, Micale N, Pinto A, De Micheli C, Conti P.. (2013) Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis., 56 (14): [PMID:23611656] [10.1021/jm301424d] |
4. Bhattacharjee A, Sinha A, Ratia K, Yin L, Delgado-Rivera L, Petukhov PA, Thatcher GRJ, Wardrop DJ.. (2017) 2-Arylidene Hydrazinecarbodithioates as Potent, Selective Inhibitors of Cystathionine γ-Lyase (CSE)., 8 (12): [PMID:29259741] [10.1021/acsmedchemlett.7b00313] |
Source(1):